Publication highlight: Treatment of food allergy: Oral immunotherapy, biologics, and beyond
In the review article published this April in Annals of Allergy, Asthma, & Immunology, Sindher et al summarizes the food allergy clinical trials studying the use of biologics targeting pathways such as immunoglobulin E, interterleukin-4, interleukin-13, and alarmins which drive allergic reactions. These biologicals include therapeutics such as omalizumab which have already shown great promise for the treatment of food allergy as well as other therapeutics such as dupilumab which have been approved by the FDA for the treatment of other allergic diseases such as asthma and are currently being investigated in food allergy. For more information on the use of these therapeutics in food allergy, see the full article HERE. https://www.annallergy.org/article/S1081-1206(23)00309-5/fulltext
By Andrew Chin
Andrew Chin is a scientific grant writer at the Sean N. Parker Center who works closely with Drs. Chinthrajah and Sindher to assist with the Center's manuscripts, grants presentations, and other aspects of scientific writing. His background in basic research allows him to bring complementary insights to the clinical research in the Center.
